Metropolitan Life Insurance Company (MetLife)’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-3,833
| Closed | -$162K | – | 2260 |
|
|
2024
Q1 | $162K | Sell |
3,833
-156
| -4% | -$6.59K | 0.01% | 799 |
|
|
2023
Q4 | $169K | Buy |
3,989
+367
| +10% | +$15.6K | 0.01% | 816 |
|
|
2023
Q3 | $79.1K | Buy |
3,622
+224
| +7% | +$4.89K | ﹤0.01% | 1144 |
|
|
2023
Q2 | $108K | Buy |
3,398
+103
| +3% | +$3.27K | 0.01% | 978 |
|
|
2023
Q1 | $80.4K | Sell |
3,295
-292
| -8% | -$7.12K | ﹤0.01% | 1118 |
|
|
2022
Q4 | $113K | Buy |
3,587
+240
| +7% | +$7.57K | 0.01% | 984 |
|
|
2022
Q3 | $94.6K | Hold |
3,347
| – | – | ﹤0.01% | 1052 |
|
|
2022
Q2 | $88.5K | Buy |
3,347
+544
| +19% | +$14.4K | ﹤0.01% | 1128 |
|
|
2022
Q1 | $98.1K | Sell |
2,803
-9,285
| -77% | -$325K | ﹤0.01% | 1204 |
|
|
2021
Q4 | $392K | Buy |
12,088
+355
| +3% | +$11.5K | 0.01% | 1585 |
|
|
2021
Q3 | $346K | Sell |
11,733
-420
| -3% | -$12.4K | 0.01% | 1674 |
|
|
2021
Q2 | $311K | Buy |
+12,153
| New | +$311K | ﹤0.01% | 1835 |
|